decisionhealth Newsletters, Part B News - 2019 Issue 12 (December)
Medicare OKs esketamine therapy for major depression, but prepare for hurdles
Subscribe or sign in to view the full article.
Article Overview
This article covers a new Medicare physician fee schedule service related to in-office esketamine treatment for depression that has not responded to oral antidepressants. It explains the broader billing and operational context for practices, including supervision, observation, enrollment requirements, and the fact that coverage comes with unusual administrative hurdles. It is useful for physicians, coders, billing staff, and practice managers who need to understand the general scope of the new Medicare guidance and the type of documentation and program rules involved.
Why This Topic Matters
The article matters because it signals a new Medicare payment pathway for a specialized depression treatment while also highlighting significant operational and compliance requirements that practices must address before offering the service.
Article Sections
-
Coding
Overview of the Medicare payment change and the setting in which the service is furnished. The section introduces the new HCPCS reporting framework and the related supervision and observation context.
What You Will Learn
- How Medicare’s physician fee schedule update affects in-office esketamine treatment for depression
- What operational requirements may apply to practices offering the service
- How the article frames the relationship between Medicare billing and REMS-related program requirements
- Why private payer policies may be useful for understanding broader medical-necessity expectations
Who Should Read This
- Physicians
- Medical coders
- Billing staff
- Practice managers
- Compliance professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com